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Background & Objective: Carbapenem-resistant Enterobacteriaceae is a growing 
concern worldwide including Iran. The emergence of this pathogen is worrying as 
carbapenem is one of the 'last-line' antibiotics for treatment of infections caused by 
multi drug resistant gram- negative bacteria. The main objective of this study was to 
determine the prevalence of carbapenem-resistant Enterobacteriaceae in a referral 
hospital in Tehran, Iran. 
Methods: In this study, all positive isolates of Enterobacteriaceae recorded in blood, 
urine, and other body fluids were studied during April 2017 to April 2018 in a referral 
hospital in Tehran. All cases of resistance to carbapenems were first tested by modified 
Hodge test. All cases with positive or negative test, after gene extraction, were examined 
genotypically based on the primers designed for the three Klebsiella pneumoniae 
carbapenemase (KPC), New Delhi metallo-β-lactamase (NDM), and OXA-48 genes by 
conventional PCR method. 
Results: 108 isolates (13.6%) were resistant to all cephalosporins as well as to 
imipenem and meropenem. In a genotypic study, including 45 isolates, 13 isolates were 
positive for OXA-48 gene, 11 isolates for OXA-48 and NDM genes, 11 isolates for OXA-
48, NDM and KPC genes, 4 isolates for OXA-48 genes and KPC, 3 isolates for NDM, 
one isolate for KPC. On the other hand, two isolates were negative for all three genes 
examined. 
Conclusion: OXA-48 gene was one of the most common genes resistant to 
carbapenems in Iran. According to studies, the prevalence of antibiotic resistance in 
Iran is rising dramatically, which reduces the choice of antibiotics to treat severe 
infections in the future. 
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Introduction 
Emergence of carbapenem-resistant Enterob-
acteriaceae is being reported increasingly worldwide 
and is becoming an important issue in health care 
systems (1). 
Nosocomial infections, a major public healthcare 
problem, are more prevalent in developed countries 
because of the related mortality and socioeconomic 
costs (2). Enterobacteriaceae is one of the major 
causative agents of nosocomial infections (3,4).  
Gram-negative bacteria of the Enterobacteriaceae 
family are important causes of urinary tract infections 
(UTIs), bloodstream infections, hospital- and 
healthcare-associated pneumonias, and various intra-
abdominal infections (5). 
Emerging resistance in Enterobacteriaceae is a 
significant problem which requires immediate 
attention. (5). 
The carbapenem group (e.g., imipenem, 
meropenem) is a safe and generally effective therapeutic 
choice for the treatment of severe gram-negative 
bacterial infections when resistance to other classes of 
antimicrobials is present (6). Due to their broad-
spectrum activity, these antibiotics are commonly used 
in the treatment of life-threatening infections. Excessive 
and inappropriate use of these drugs, has led to an 
increased resistance to carbapenems. This issue is one of 
the main causes of the expression of carbapenemase 
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genes such as IMP, VIM, NDM, OXA-48, and KPC 
among the members of this family (7). 
The production of acquired carbapenemase 
significantly limits the choice of antibiotic treatment 
infections caused by Gram-negative bacteria (8). 
More seriously, Enterobacteriaceae with carba-
penem-hydrolyzing-lactamases are an emerging 
problem (9). OXA-48 carbapenemase (Ambler class 
D) was first reported in Enterobacteriaceae in Turkey 
in 2001 (10,11).  
Subsequently, spread has been reported not only 
across Turkey but also in the Middle-East, North 
Africa, and Europe (12). The KPC constitutes the 
most common class A carbapenemase in Klebsiella 
pneumoniae which was first reported in 1996 in the 
USA, though current reports reveal their presence in 
Europe, Asia, and South America (13). 
New Delhi Metallo-beta-lactamase was first reported 
in K. pneumonia and Escherichia coli isolated from a 
59-year-old Swedish patient from India who was 
previously admitted to a hospital in New Delhi (14). The 
main objective of this study is to show the prevalence of 
carbapenem-resistant Enterobacteriaceae and to 
investigate the presence of carbapenemase genes in 
Enterobacteriaceae clinical isolates resistant to 
carbapenem antibiotics from hospitalized patients in a 
university referral hospital in Tehran, Iran. 
Materials and Methods 
Clinical Isolates 
A total of 800 Enterobacteriaceae isolates were 
collected from various clinical specimens including 
urine (n=473), tracheal aspirate (n=19), broncho 
alveolar-lavage (BAL) fluid (n=11), wound (n=44), 
cerebrospinal fluid (n=2), sputum (n=78), catheter 
(n=9), other sterile body fluid (n=99), and blood ( 
n=63) between April 2017 and April 2018 from 
hospitalized patients at Rasoul Akram hospital, one of 
the referral university hospitals of Tehran, Iran. 
Bacterial Isolation and Identification 
All samples were routinely cultured on 
MacConkey and blood agar plates. Blood samples 
were cultured in Blood culture bottles. The isolates 
were identified at the species level using standard 
biochemical tests and microbiological methods such 
as colony types, motility, carbohydrate fermentation 
of glucose, lactose and sucrose, Triple Sugar Iron 
(TSI), Simmons citrate, SIM (Sulfide, Indole, 
Motility), Methyl Red, and urease. These are common 
biochemical tests used for identifying different 
species of Enterobacteriaceae (15). 
Antibiotic Susceptibility Test 
The tested antibiotics were amikacin and 
gentamicin (aminoglycosides); ampicillin-sulbactam, 
and piperacillin-tazobactam (β-lactams); cephazolin, 
cefepime, cefotaxime, ceftazidime, (cephalosporins); 
ciprofloxacin (quinolone); Sulfamethoxazole / 
Trimethoprim; colistin (polymyxin), imipenem and 
meropenem (carbapenems) and Nitrofurantoin (in 
urinary infection) (MAST company, Germany). They 
were investigated using the disc-diffusion method as 
described in Clinical and Laboratory Standards 
Institute (CLSI) guidelines (16). We used E. coli 
ATCC 25922 as a carbapenem-susceptible strain, and 
K. pneumoniae AO 8053 as a carbapenem resistant for 
quality control. MIC to meropenem was determined 
by E-test strips (Liofilchem company, Italy), 
according to the manufacturer’s instructions and 
CLSI 2015 guidelines. The isolates with MIC values 
≥4 μg/mL ;2 μg/ mL and ≤1 μg /mL for meropenem 
were considered as resistant, intermediate, and 
susceptible, respectively (16). 
Phenotypic determination of carbapenemases was 
performed using the modified Hodge test (MHT). The 
MHT was carried out according to CLSI guidelines 
using a 10μg disc of ertapenem on Muller–Hinton 
agar plates. Following overnight incubation, the 
presence of a “cloverleaf shaped” inhibition zone was 
interpreted as a positive result. E. coli ATCC 25922 
was used as the carbapenem susceptible strain (17). 
Molecular Detection of Genes Encoding 
Carbapenemases 
Genomic DNA isolates was obtained from 
Entrobacteriaceae by boiling two or three colonies of 
each isolate in 500 mL of distilled water for 10 min and 
centrifugation at 10,000 rpm for 10 min. The supernatant 
was used as a template for polymerase chain reaction 
(PCR) assay. PCR assays were carried out for detection 
of KPC, NDM, and OXA-48 genes using a set of specific 
primers as previously described (Table 1) (2,18–21).  
Standard strains for blaOXA-48, blaNDM, and blaKPC 
genes were provided by the Pasteur Institute of Iran. The 
study was approved by the ethics committee of the Iran 
University of Medical Sciences with the (code: 
IR.IUMS.FMD.REC.1396.9411100003 ). 
 
Table 1. The sequencing primers used in this study 
Gene 3ˊ–5ˊ  Primer Product size (bp) Annealing Temperature (C) References 
KPC-Fm CGTCTAGTTCTGCTGTCTTG 798 60 (2) 
KPC-Rm CTTGTCATCCTTGTTAGGCG  60 (2) 
NDM-F GGTTTGGCGATCTGGTTTTC 621 55 (2) 
NDM-R CGGAATGGCTCATCACGATC  55 (2) 
OXA-48-F GCGTGGTTAAGGATGAACAC 438 55 (2) 
OXA-48-R CATCAAGTTCAACCCAACCG  55 (2) 
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Statistical Analysis 
Data was presented as mean and standard deviation 
for quantitative variables, and percentage for qualitative 
variables. The correlation between the variables was 
assessed by Pearson correlation test. Mann-Whitney U 
test or t-test was applied to compare quantitative 
variables. SPSS 22 (IBM Corp., Armonk, NY, USA) 
was used to analyze the statistical variables. P-values 




Here, 108 (13.6%) of 800 Enterobacteriaceae 
isolates (481 E. coli, 291 K. pneumoniae, 8 Enterobacter 
and 20 other Enterobacteriaceae ( collected were 
carbapenem-resistant Enterobacteriaceae (CRE) 
consisting of K. pneumoniae (n=102), E. coli (n=4), and 
Enterobacter (n=2). Carbapenem-resistant was 35% in 
K. pneumoniae, 25% in Enterobacter and less than 1% 
in E. coli isolates. 
A total of 72 isolates (66.66%) were isolated from 
ICU wards, while the remaining isolates were recovered 
from other wards. The isolates were predominantly 
collected from sputum (29/108; 27%), urine (24/96; 
25%), wound secretions (10/108; 9.5%), %), broncho 
alveolar lavage (BAL) (9/108; 8.5%), catheter (3/108; 
3%), tracheal secretions (2/108; 1.85%), CSF (1/108; 
1%), and other sites of isolation (18/108; 16%). Most 
carbapenem-resistant K. pneumoniae isolates were 
obtained from respiratory specimens including sputum, 
tracheal secretions, and BAL (39/102; 38%) and urine 
specimens (22/102; 21.5%).  
Both carbapenem-resistant Enterobacters were 
isolated from blood cultures, separated from the same 
ICU ward. Carbapenem-resistant E. coli were isolated 
from urine (2/4;50%), sputum (1/4; 25%) and wound 
secretion (1/4; 25%) specimen. Interestingly, three of 
the four isolates were found in the same ICU ward. 
 The age of patients ranged from 16 years to 91 
years (mean = 58.53 years). Male-to-female ratio was 
1.66 and 59% of patients were over 60 years old. The 
isolates from intensive care units covered 67% of 
carbapenem-resistant Enterobacteriaceae, which 
included 100% of E. coli and Enterobacter but 65% of 
K. pneumoniae. 
Antimicrobial Susceptibility Testing 
Overall, all isolates were resistant to at least three 
classes of antibiotics and they were considered as 
MDR. The rates of resistance to imipenem and 
meropenem among isolates were 90% (97/108) and 
96.4% (104/108), respectively. The percentages of 
resistance to other antimicrobial agents were as 
follows: colistin 5.5% (6/108); trimethoprim 
/sulfamethoxazole 80% (86/108); amikacin 89% 
(96/108); and nitrofurantoin 71.5% (17/24). All 
isolates demonstrated resistance to ceftazidime, 
cefepime, cefazolin, cefotaxime, ciprofloxacin, 
ampisulbactam-piperacillin. 
Of the 45 carbapenem resistant entrobacteriaceae 
isolates, all were high-level meropenem-resistant (MIC 
≥ 4), except for 4 isolates. The lowest and highest level 
of meropenem MIC for carbapenem-resistant isolates 
were estimated 0.16 mg/L and >32 mg/L, respectively.  
The results of MHT revealed that 33 of 45 carbapenem-
resistant isolates were carbapenemase producing ones. 
Detection of Carbapenemases 
Forty-five isolates were included in the molecular 
study as CRE. Overal, of these 45 CREs, 13 (28.88%) 
harbored only the OXA-48 gene; 3 (6.66%) carried only 
the NDM gene, and 1 (2.22%) carried only the KPC 
gene. Further, 11 (24.44%) of these isolates co-
produced the NDM and OXA-48 genes; 4 (8.8%) co-
produced the OXA-48 and KPC; and 11 (24.44%) co-
produced the NDM, OXA-48, and KPC genes. Two 
isolates were negative for all 3 genes. There was no 
statistical association between the source of infections 
and gene expression (P=0.32). The results of tests 
performed in Carbapenem producing Entero-
bacteriaceae are summarized in Table 2. Figure 1 
shows a PCR product of blaOXA-48 gene. The first 
column represents the ladder and the last two columns 
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Table 2. Characteristics of carbapenem producing Enterobacteriaceae 
Isolates Age/Gender MIC MHT Genes Ward Specimen Outcome 
1(K. 
pneumonia) 
27/Female >32 positive OXA48+NDM+KPC SICU Tracheal Survived 
2(K. 
pneumonia) 
67/Female >32 positive OXA48+NDM1+KPC ICU tracheal Died 
3(K. 
pneumonia) 
54/Female >32 positive OXA48+NDM+KPC Post CCU pancreas Survived 
4(K. 
pneumonia) 
56/Male >32 positive OXA48+KPC SICU Sputum Survived 
5(K. 
pneumonia) 
68/Male >32 positive OXA48+NDM+KPC MICU Sputum Died 
6(K. 
pneumonia) 
47/Male >32 positive OXA48+NDM+KPC Neuro ICU Unknown Died 
7(K. 
pneumonia) 
62/Femal >32 positive OXA48+NDM+KPC SICU Blood Died 
8(K. 
pneumonia) 
21/Femal >32 positive NDM1 Gynecology Urine Survived 
9(K. 
pneumonia) 
78//Femal >32 positive OXA48+NDM MICU Sputum Died 
10(K. 
pneumonia) 
80/Femal >32 positive OXA48+NDM MICU Sputum Died 
11(K. 
pneumonia) 
65/Femal >32 positive OXA48+NDM+KPC MICU Urine Survived 
12(K. 
pneumonia) 
23/Male 12 Negative OXA48 MICU Sputum Died 
13(K. 
pneumonia) 
62/Male >32 Negative Non MICU Sputum Died 
14(K. 
pneumonia) 
35/Male >32 positive OXA48+NDM+KPC ICU CVP Survived 
15(K. 
pneumonia) 
72/Male >32 positive OXA48+NDM+KPC MICU Sputum Died 
16(K. 
pneumonia) 






55/Male >32 Negative Non MICU Sputum Died 
18(K. 
pneumonia) 
64/Male >32 positive OXA48+NDM MICU Sputum Survived 
19(Entrobacter) 73/Male >32 positive OXA48+NDM ICU Blood Died 
20(K. 
pneumonia) 
62/Male >32 positive OXA48+NDM+KPC MICU Urine Died 
21(K. 
pneumonia) 




22(Entrobacter) 71/Female >32 positive OXA48+NDM ICU Blood Died 
23(K. 
pneumonia) 
60/Male >32 positive OXA48+NDM+KPC MICU Blood Died 
24(K. 
pneumonia) 
73/Male >32 Negative OXA48 ICU Sputum Died 
25(K. 
pneumonia) 
70/Female >32 Negative OXA48 ICU Sputum Died 
26(K. 
pneumonia) 
84/Female >32 positive OXA48 Nephrology Urine Survived 
27(K. 
pneumonia) 
46/Male 0.16 positive OXA48 Infectious Catheter Survived 
28(K. 
pneumonia) 
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Isolates Age/Gender MIC MHT Genes Ward Specimen Outcome 
29(K. 
pneumonia) 
71/Female 6 Negative OXA48 MICU Pleura Fluid Died 
30(K. 
pneumonia) 
75/Female  positive KPC SICU Ascites fluid Died 
31(E. coli) 75/Male 6 Negative OXA48 Neuro ICU Urine Died 
32(E. coli) 29/Male 4 positive OXA48+KPC Neuro ICU Urine Survived 
33(K. 
pneumonia) 
74/Female 4 positive OXA48+KPC SICU Urine Died 
34(K. 
pneumonia) 
36/Female 3 Negative OXA48 Medical Sputum Survived 
35(K. 
pneumonia) 
37/Male 6 Negative OXA48 ICU Unknown Died 
36(K. 
pneumonia) 












40/Female 32 Negative NDM Neuro ICU Sputum Died 
39(K. 
pneumonia) 
38/Male 32 Negative NDM MICU Urine Died 
40(K. 
pneumonia) 
77/Male 6 positive OXA48+NDM ICU Sputum Died 
41(K. 
pneumonia) 
84/Female >32 positive OXA48+NDM Nephrology Urine Died 
42(K. 
pneumonia) 
89/Male >32 positive OXA48+NDM Medical Urine Survived 
43(K. 
pneumonia) 
61/Male >32 positive OXA48+NDM Medical Urine Survived 
44(K. 
pneumonia) 
42/Male >32 positive OXA48+NDM Neuro ICU Sputum Died 
45(K. 
pneumonia) 
48/Male >32 positive OXA48 SICU Unknown Survived 
 
Discussion 
Antibiotic resistance, especially simultaneous 
resistance to multiple classes of antibiotics 
(multiresistance), is an increasing global problem. 
Gram-negative bacteria, in particular the 
Enterobacteriaceae, are adapted to exchanging genetic 
information and antibiotic resistance. In these 
organisms, this is often due to the acquisition of genes 
from a shared pool (22). Resistance to carbapenems 
amongst Enterobacteriaceae is usually mediated by 
transferable beta-lactamase enzymes. Due to frequent 
occurrence of other resistance genes on the same mobile 
genetic elements, strains producing carbapenemases are 
normally extensively drug resistant (23). 
 The emergence of carbapenemases in 
Enterobacteriaceae is of great concern as these provide 
a far more efficient and stable mechanism of resistance 
to carbapenems than combinations of an ESBL and 
impermeability. Bacteria carrying these resistance 
determinants are often resistant to other treatment 
options, due to the frequent co-acquisition of non-beta-
lactam resistance genes located on the same mobile 
genetic elements. Further, acquired carbapenemases 
have the potential for sepsis (23,24).  Although the 
presence of CRE have repeatedly been documented, 
larger scale, systematic studies with molecular 
investigations are still few in Iran (25). The prevalence 
of CRE in 2017-2018 collected at Rasoul Akram 
hospital was 13.6% in general. Specifically, the 
prevalence of carbapenems resistance in K. 
pneumoniae was 35%; in Enterobacter 25%, and in E. 
coli less than 1%. On the other hand, in Solgi et al.’s 
study in 2015-2016 done in Isfahan, prevalence of 
CPKP was 41.7% (20). In this study, two Enterobacter 
isolates were obtained from the same ICU ward and 
from blood culture of patients at the same time. Also 
their gene presence was identical. 3 out of 4 
carbapenem-resistant E. coli cases were obtained from 
the same ICU ward. They were all isolated from urine 
samples. Their gene presence was also identical. All 
instances of carbapenem resistance Entrobacteriaceae 
in the MICU ward were K. pneumoniae, and their gene 
presence was also similar except for one. This 
demonstrates the importance of infection control in 
hospital wards. 
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 The highest number of clinical isolates was 
collected from the respiratory tract and in the MICU. 
The highest antibiotic resistance was observed for 
cephalosporins and carbapenems while the least 
resistance to colistin and trimethoprim/ 
sulfamethoxazole. In the present study, the rate of 
antibiotic resistance with some variation which may 
arise from the source of infections and geographical 
distribution was comparable with the previous reported 
studies in Iran (18,20,26,27). The administration of 
multiple antibiotics has been reported as a risk factor 
for carbapenem resistance acquisition (28). Findings 
by Patel et al. showed that carbapenem resistance is not 
attributed only to previous exposure to carbapenem but 
also exposure to other antibiotics (29). In our study, the 
ratio of male to female was 1.66, while in Kuwait, 
Arabian Peninsula, Malaysian studies, the male to 
female ratios were 0.9, 1.8, and 1.2, respectively. (30–
32). In our study, 52.77% of the resistant group died, 
which was significantly (P=0.043) in contrast to the 
carbapenem-sensitive group, where only 12.87% died. 
In the Kuwait study, 71.42% of the patients survived 
while 28.57% died (30). Dautzenberg and co-workers 
have reported that patients colonized with carbapenem 
resistant Enterobacteriaceae have higher mortality 
rates as compared to non-colonized patients due to long 
hospitalization (33). These results are consistent with 
the results of our study. Risk factors for infection with 
carbapenemase- producing Enterobacteriaceae (CPE) 
include hospitalization (particularly in intensive care 
units), mechanical ventilation, indwelling catheters, 
comorbidities, transplantation, exposure to broad-
spectrum antibiotics and previous colonization with 
these strains (23). This may be the cause of higher 
mortality in this group and requires further 
investigation. Considering the frequency of isolates 
resistant to carbapenem, according to the 
hospitalization wards, in our study, 67% of isolates 
were isolated from intensive care units. Similarly, in 
Solgi's study in Isfahan, 77% of the cases were isolated 
from intensive care units (20). However, in the 
Malaysian study, the highest percentages were 
observed in the surgical ward (25%) and internal ward 
(25%), some of whom were also admitted to the 
intensive care unit (32). 
Our data regarding strains collected in one of 
referral hospital in Tehran is in accordance with 
previous reports that the most common mechanism of 
carbapenem resistance in CRE isolates of Tehran are 
the production of OXA-48-like and NDM 
carbapenemases (20). 
This study found CPE with OXA-48, NDM and 
KPC genes together or alone, in a hospital in Tehran. 
The co-production of OXA-48- and NDM; OXA-48 and 
KPC with NDM -producing K. pneumoniae has been 
reported in some Asian and European countries (30–
32,34–36). Beyond the dominance of OXA-48-like and 
NDM producing strains, it was also notable that almost 
half of the collection co-produced these two enzymes. 
Although, dual carbapenemase producing K. 
pneumoniae were encountered in Iran earlier (20). 
Their occurrence with such frequency has not been 
noted yet. To the best of our knowledge, this report 
presented the first identification of OXA-48 and KPC 
with NDM -producing K. pneumoniae in Iran. 
Genes of the OXA-48 type and related OXA 
enzymes have been found to be widely prevalent in 
North Africa, the Middle East, and the Indian 
subcontinent (12). And, more importantly, large 
numbers of outbreaks have occurred in regions such as 
Europe and Australia, where CRE is not endemic, as a 
result of international transfer of patients (12,37). The 
first report of OXA-48 gene in Iran was by Azimi et al. 
in Tehran 2014, in 27 carbapenem-resistant K. 
pneumoniae isolates recovered from burn patients (1). 
It was subsequently re-identified in Iran (20,27). The 
widespread prevalence of OXA-48-positive 
carbapenem resistant K. pneumoniae strains has been 
reported in several Asian and European countries 
including Turkey, Saudi Arabia, Taiwan, China, Russia 
and France which has become an expanding problem 
(11,32,38–42). 
A majority of NDM cases reported worldwide were 
related to travel or hospitalization in the Indian 
subcontinent such as India and Pakistan (9). However, 
in our study, the NDM positive patient had no record 
of prior travel outside Iran. The presence of blaNDM 
without any association with international travel has 
also been reported by Rimrang and coworkers (43) 
which indicated that the NDM gene was acquired 
locally. The first report on the detection of NDM in Iran 
was by Shahcheraghi et al. in 2012 during a study on 
Enterobacteriaceae family isolates collected from five 
hospitals in Tehran (18). NDM was also reported by 
Fazeli and Solgi et al. (44,45). KPC is endemic in 
northeastern regions in the USA, Greece and Israel but 
cross regional spreading into United Kingdom, Brazil, 
Sweden, India and China had been reported recently 
(46). The first report of KPC in Iran was made by 
Nobari and his colleagues in 2012 (21). This gene is 
often detected on mobile genetic elements such as 
plasmids and transposons which facilitates its rapid 
dissemination worldwide (47). 
Regarding the prevalence of carbapenemase 
resistant genes in our study, the most frequent genes 
were OXA-48 in 13 cases (28.88%), co-produced OXA-
48 and NDM in 11 cases (24.44%), simultaneous 
expression of co-produced NDM, OXA-48, and KPC In 
11 cases (24.44%), co-produced OXA-48 and KPC in 4 
cases (8.88%), NDM in 3 cases (6.66%), and KPC in 
one case (2.2%), revealing that the highest frequency 
belonged to OXA-48. OXA-48 (58.3%) and the co-
produced OXA-48 and NDM in 35.4% of cases have 
been reported in Solgi's study in Isfahan. However, no 
case of KPC was reported (20). Only clinical isolates 
were included in our study whereas the study By Solgi 
et al. was focused on rectal swabs (48). OXA-48 
expression in 37.5% of cases and co-produced OXA-48 
and KPC were also found in 37.5% of cases, with one 
case harboring KPC gene in the Malaysian study (32). 
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However, in the Arabian Peninsula, the NDM gene 
was found in 46.5% of cases and OXA-48 in 32.5% of 
cases while their co-produced version was reported in 
3.5% of cases (31). In the Kuwait study, NDM gene 
was reported in 57.1% of isolated and the co-produced 
version of the three genes and that of NDM and OXA-
48 was reported in 33.33% and 9.52% of cases, 
respectively (30). Based on Solgi's study, they found 
that intestinal carriage rates of NDM and OXA-48- 
producing Enterobacteriaceae are high, suggesting that 
NDM and OXA-48 have become endemic (48). 
Additionally, recent observations in neighboring 
countries, such as Kuwait (49) and Lebanon (50), 
indicates the emergence of this resistance mechanism 
in the Middle East. We could not find any of the 
targeted genes in the 2 carbapenem-resistant isolates, 
so their resistance to carbapenems may be due to other 
mechanisms including production of extended-
spectrum beta-lactamases (ESBLs), AmpC 
betalactamases, decreased permeability of outer 
membrane or efflux pumps activity, or probably the 
presence of other genes that were not studied in this 
research (51) .Concurrent presence of carbapenemic 
genes in bacteria causes many concerns for physicians 
in the hospital as they cause hydrolysis of all β-lactam 
antibiotics as an important treatment option. 
Furthermore, the transfer of these genes among carriers 
and patients admitted in hospital increases the 
prevalence of the disease, which is difficult to control 
(52,53). 
This study is limited by its small sample size as it 
only includes the carbapenem resistant 
Entrobacteriacae which were isolated during a 12 
months period. Thus, the findings cannot be 
generalized to a broader population based on this study 
alone as it may include potential biases. A further 
limitation of our study is the high number of unknown 
or missing values in the analysis of potential risk 
factors. This reflects the difficulty to obtain 
information such as, previous hospitalization and travel 
history since microbiological laboratories often have 
no direct access to these data. 
The present study suggested that the isolates of 
carbapenemase-producing Enterobacteriaceae have a 
high prevalence in patients admitted to our hospital. 
The presence of these genes upon transference of one 
strain to another strain, rapid detection of 
carbapenemase-producing isolates in clinical 
specimens, as well as rapid and accurate screening of 
patient carriers at the first stage of admission to 
hospitals to prevent dissemination of these strains are 
very important at the both hospital and community 
level. Undoubtedly, the emergence and release of these 
genes in the future will reduce the choice of antibiotics 
suitable for the treatment of severe infections. 
Ultimately, this will seriously threat the human health 
and healthcare system of the country. Therefore, it is 
imperative that a continuous monitoring system and 
strong programs to control the hospital infection should 
be used to prevent further dissemination in health 
centers and in the community. Otherwise, one of the 
biggest problems we face in the future is the loss of an 
important antibiotic treatment line, carbapenem, an 




We thank professor Shahcheraghi for providing us 
the blaKPC; blaNDM and blaOXA48-positive controls. 
We would like to appreciate the department of 
microbiology of Pasteur Institute of Iran for helping us 
in molecular techniques. This work was funded by 
research grants from the Iran University of Medical 
Sciences (Project No.1428).  
 
Conflict of Interest 
The authors declared that there is no conflict of 
interest regarding the publication of this article. 
 
References 
1. Azimi L, Nordmann P, Lari AR, Bonnin RA. First report 
of OXA-48-producing Klebsiella pneumoniae strains in 
Iran. GMS Hyg Infect Control [Internet]. 
2014;9(1):Doc07. 
2. Shahcheraghi F, Aslani MM, Mahmoudi H, Karimitabar 
Z, Solgi H, Bahador A, et al. Molecular study of 
carbapenemase genes in clinical isolates of 
Enterobacteriaceae resistant to carbapenems and 
determining their clonal relationship using pulsed-field 
gel electrophoresis. J Med Microbiol [Internet]. 2017 
May 1;66(5):570-6. [DOI:10.1099/jmm.0.000467] 
[PMID] 
3. Dortet L, Poirel L, Nordmann P. Worldwide 
Dissemination of the NDM-Type Carbapenemases in 
Gram-Negative Bacteria. Biomed Res Int [Internet]. 
2014;2014:1-12. [DOI:10.1155/2014/249856] [PMID] 
[PMCID] 
4. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, 
Pollock DA, et al. Antimicrobial-Resistant Pathogens 
Associated With Healthcare-Associated Infections: 
Annual Summary of Data Reported to the National 
Healthcare Safety Network at the Centers for Disease 
Control and Prevention, 2006-2007. Infect Control Hosp 
Epidemiol [Internet]. 2008 Nov 2;29(11):996-1011. 
[DOI:10.1086/591861] [PMID] 
5. Paterson DL. Resistance in Gram-Negative Bacteria: 
Enterobacteriaceae. Am J Med [Internet]. 2006 
Jun;119(6):S20-8. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0002934306
003445 [DOI:10.1016/j.amjmed.2006.03.013] [PMID] 
6. MCKIBBEN L, HORAN T, TOKARS J, FOWLER G, 
CARDO D, PEARSON M, et al. Guidance on Public 
Reporting of Healthcare-Associated Infections: 
Recommendations of the Healthcare Infection Control 
Practices Advisory Committee. Am J Infect Control 
[Internet]. 2005 May;33(4):217-26. 
[DOI:10.1016/j.ajic.2005.04.001] [PMID] 
7. Patel JB, Rasheed JK, Kitchel B. Carbapenemases in 
Enterobacteriaceae: Activity, Epidemiology, and 
Kosar Jalalvand et al. 93 
Vol.15 No.2 Spring 2020                                                                                    IRANIAN JOURNAL OF PATHOLOGY 
Laboratory Detection. Clin Microbiol Newsl [Internet]. 
2009 Apr 21;31(8):55-62. 
[DOI:10.1016/j.clinmicnews.2009.03.005] 
8. Hrabák J, Chudáčkova E, Papagiannitsis CC. Detection 
of carbapenemases in Enterobacteriaceae: a challenge for 
diagnostic microbiological laboratories. Clin Microbiol 
Infect [Internet]. 2014 Sep;20(9):839-53. 
[DOI:10.1111/1469-0691.12678] [PMID] 
9. Woodford N, Johnson AP. Global spread of antibiotic 
resistance: the example of New Delhi metallo-β-
lactamase (NDM)-mediated carbapenem resistance. J 
Med Microbiol [Internet]. 2013 Apr 1;62(4):499-513. 
[DOI:10.1099/jmm.0.052555-0] [PMID] 
10. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence 
of Oxacillinase-Mediated Resistance to Imipenem in 
Klebsiella pneumoniae. Antimicrob Agents Chemother 
[Internet]. 2004 Jan 1;48(1):15-22. 
[DOI:10.1128/AAC.48.1.15-22.2004] [PMID] [PMCID] 
11. Gülmez D, Woodford N, Palepou M-FI, Mushtaq S, 
Metan G, Yakupogullari Y, et al. Carbapenem-resistant 
Escherichia coli and Klebsiella pneumoniae isolates from 
Turkey with OXA-48-like carbapenemases and outer 
membrane protein loss. Int J Antimicrob Agents 
[Internet]. 2008 Jun;31(6):523-6. 
[DOI:10.1016/j.ijantimicag.2008.01.017] [PMID] 
12. Poirel L, Potron A, Nordmann P. OXA-48-like 
carbapenemases: the phantom menace. J Antimicrob 
Chemother [Internet]. 2012 Jul 1;67(7):1597-606. 
[DOI:10.1093/jac/dks121] [PMID] 
13. Munoz‐Price LS, Quinn JP. The Spread of Klebsiella 
pneumoniae Carbapenemases: A Tale of Strains, 
Plasmids, and Transposons. Clin Infect Dis [Internet]. 
2009 Dec;49(11):1739-41. [DOI:10.1086/648078] 
[PMID] 
14. Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection 
of NDM-1-producing Klebsiella pneumoniae in Kenya. 
Antimicrob Agents Chemother [Internet]. 2011 
Feb;55(2):934-6. [DOI:10.1128/AAC.01247-10] 
[PMID] [PMCID] 
15. Mahon CR, Lehman D, Manuselis Jr G. Textbook of 
Diagnostic Microbiology. 4th ed. 2014. 
16. Institute C and LS. Performance Standards for 
Antimicrobial Susceptibility Testing; Twenty-Fifth 
Informational Supplement. CLSI document M100-S23. 
Wayne, PA 19087 USA; 2015. 
17. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. 
Modified Hodge and EDTA-disk synergy tests to screen 
metallo-beta-lactamase-producing strains of 
Pseudomonas and Acinetobacter species. Clin Microbiol 
Infect [Internet]. 2001 Feb;7(2):88-91. 
[DOI:10.1046/j.1469-0691.2001.00204.x] [PMID] 
18. Shahcheraghi F, Nobari S, Rahmati Ghezelgeh F, Nasiri 
S, Owlia P, Nikbin VS, et al. First Report of New Delhi 
Metallo-Beta-Lactamase-1-Producing Klebsiella 
pneumoniae in Iran. Microb Drug Resist [Internet]. 2013 
Feb;19(1):30-6. [DOI:10.1089/mdr.2012.0078] [PMID] 
19. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex 
PCR for detection of acquired carbapenemase genes. 
Diagn Microbiol Infect Dis [Internet]. 2011 
May;70(1):119-23. 
[DOI:10.1016/j.diagmicrobio.2010.12.002] [PMID] 
20. Solgi H, Badmasti F, Giske CG, Aghamohammad S, 
Shahcheraghi F. Molecular epidemiology of NDM-1- 
and OXA-48-producing Klebsiella pneumoniae in an 
Iranian hospital: clonal dissemination of ST11 and 
ST893. J Antimicrob Chemother [Internet]. 2018 Jun 
1;73(6):1517-24. [DOI:10.1093/jac/dky081] [PMID] 
21. Nobari S, Shahcheraghi F, Rahmati Ghezelgeh F, 
Valizadeh B. Molecular Characterization of 
Carbapenem-Resistant Strains of Klebsiella pneumoniae 
Isolated from Iranian Patients: First Identification of bla 
KPC Gene in Iran. Microb Drug Resist [Internet]. 2014 
Aug;20(4):285-93. [DOI:10.1089/mdr.2013.0074] 
[PMID] 
22. Partridge SR. Analysis of antibiotic resistance regions in 
Gram-negative bacteria. FEMS Microbiol Rev [Internet]. 
2011 Sep;35(5):820-55. [DOI:10.1111/j.1574-
6976.2011.00277.x] [PMID] 
23. Tängdén T, Giske CG. Global dissemination of 
extensively drug-resistant carbapenemase-producing 
Enterobacteriaceae: clinical perspectives on detection, 
treatment and infection control. J Intern Med [Internet]. 
2015 May;277(5):501-12. [DOI:10.1111/joim.12342] 
[PMID] 
24. Thomas CP, Moore LSP, Elamin N, Doumith M, Zhang 
J, Maharjan S, et al. Early (2008-2010) hospital outbreak 
of Klebsiella pneumoniae producing OXA-48 
carbapenemase in the UK. Int J Antimicrob Agents 
[Internet]. 2013 Dec;42(6):531-6. 
[DOI:10.1016/j.ijantimicag.2013.08.020] [PMID] 
25. Zahedi Bialvaei A, Samadi Kafil H, Ebrahimzadeh 
Leylabadlo H, Asgharzadeh M, Aghazadeh M. 
Dissemination of carbapenemases producing Gram 
negative bacteria in the Middle East. Iran J Microbiol 
[Internet]. 2015 Oct;7(5):226-46. 
26. Mansury D, Motamedifar M, Sarvari J, Shirazi B, 
Khaledi A. Antibiotic susceptibility pattern and 
identification of extended spectrum β-lactamases 
(ESBLs) in clinical isolates of Klebsiella pneumoniae 
from Shiraz, Iran. Iran J Microbiol [Internet]. 2016 
Feb;8(1):55-61. 
27. Hosseinzadeh Z, Sedigh Ebrahim-Saraie H, Sarvari J, 
Mardaneh J, Dehghani B, Rokni-Hosseini SMH, et al. 
Emerge of blaNDM-1 and blaOXA-48-like harboring 
carbapenem-resistant Klebsiella pneumoniae isolates 
from hospitalized patients in southwestern Iran. J Chin 
Med Assoc [Internet]. 2018 Jun;81(6):536-40. 
[DOI:10.1016/j.jcma.2017.08.015] [PMID] 
28. Borer A, Saidel-Odes L. Limiting and controlling 
carbapenem-resistant Klebsiella pneumoniae. Infect 





29. Patel N, Harrington S, Dihmess A, Woo B, Masoud R, 
Martis P, et al. Clinical epidemiology of carbapenem-
intermediate or -resistant Enterobacteriaceae. J 
Antimicrob Chemother [Internet]. 2011 Jul 
1;66(7):1600-8. [DOI:10.1093/jac/dkr156] [PMID] 
30. Jamal WY, Albert MJ, Khodakhast F, Poirel L, Rotimi 
VO. Emergence of New Sequence Type OXA-48 
Carbapenemase-Producing Enterobacteriaceae in 
94 Evaluation of Phenotypic and Genotypic Characteristics… 
Vol.15 No.2 Spring 2020                                                                                     IRANIAN JOURNAL OF PATHOLOGY 
Kuwait. Microb Drug Resist [Internet]. 2015 
Jun;21(3):329-34. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25551428 
[DOI:10.1089/mdr.2014.0123] [PMID] 
31. Sonnevend Á, Ghazawi AA, Hashmey R, Jamal W, 
Rotimi VO, Shibl AM, et al. Characterization of 
Carbapenem-Resistant Enterobacteriaceae with High 
Rate of Autochthonous Transmission in the Arabian 
Peninsula. Cloeckaert A, editor. PLoS One [Internet]. 
2015 Jun 25;10(6):e0131372. 
[DOI:10.1371/journal.pone.0131372] [PMID] [PMCID] 
32. Low Y-M, Yap PS-X, Abdul Jabar K, Ponnampalavanar 
S, Karunakaran R, Velayuthan R, et al. The emergence of 
carbapenem resistant Klebsiella pneumoniae in 
Malaysia: correlation between microbiological trends 
with host characteristics and clinical factors. Antimicrob 
Resist Infect Control [Internet]. 2017 Dec 7;6(1):5. 
[DOI:10.1186/s13756-016-0164-x] [PMID] [PMCID] 
33. Dautzenberg MJD, Wekesa AN, Gniadkowski M, 
Antoniadou A, Giamarellou H, Petrikkos GL, et al. The 
Association Between Colonization With 
Carbapenemase-Producing Enterobacteriaceae and 




34. Brañas P, Villa J, Viedma E, Mingorance J, Orellana 
MA, Chaves F. Molecular epidemiology of 
carbapenemase-producing Klebsiella pneumoniae in a 
hospital in Madrid: Successful establishment of an OXA-
48 ST11 clone. Int J Antimicrob Agents [Internet]. 2015 
Jul;46(1):111-6. 
[DOI:10.1016/j.ijantimicag.2015.02.019] [PMID] 
35. Guo L, An J, Ma Y, Ye L, Luo Y, Tao C, et al. 
Nosocomial Outbreak of OXA-48-Producing Klebsiella 
pneumoniae in a Chinese Hospital: Clonal Transmission 
of ST147 and ST383. Forestier C, editor. PLoS One 
[Internet]. 2016 Aug 4;11(8):e0160754. 
[DOI:10.1371/journal.pone.0160754] [PMID] [PMCID] 
36. Lixandru BE, Cotar AI, Straut M, Usein CR, Cristea D, 
Ciontea S, et al. Carbapenemase-Producing Klebsiella 
pneumoniae in Romania: A Six-Month Survey. Planet PJ, 
editor. PLoS One [Internet]. 2015 Nov 
23;10(11):e0143214. Available from: 
http://dx.plos.org/10.1371/journal.pone.0143214 
[DOI:10.1371/journal.pone.0143214] [PMID] [PMCID] 
37. Espedido BA, Steen JA, Ziochos H, Grimmond SM, 
Cooper MA, Gosbell IB, et al. Whole Genome Sequence 
Analysis of the First Australian OXA-48-Producing 
Outbreak-Associated Klebsiella pneumoniae Isolates: 
The Resistome and In Vivo Evolution. Heimesaat MM, 
editor. PLoS One [Internet]. 2013 Mar 29;8(3):e59920. 
[DOI:10.1371/journal.pone.0059920] [PMID] [PMCID] 
38. Kaase M, Schimanski S, Schiller R, Beyreiß B, Thürmer 
A, Steinmann J, et al. Multicentre investigation of 
carbapenemase-producing Escherichia coli and 
Klebsiella pneumoniae in German hospitals. Int J Med 
Microbiol [Internet]. 2016 Sep;306(6):415-20. 
[DOI:10.1016/j.ijmm.2016.05.009] [PMID] 
39. Zowawi HM, Sartor AL, Balkhy HH, Walsh TR, Al 
Johani SM, AlJindan RY, et al. Molecular 
Characterization of Carbapenemase-Producing 
Escherichia coli and Klebsiella pneumoniae in the 
Countries of the Gulf Cooperation Council: Dominance 
of OXA-48 and NDM Producers. Antimicrob Agents 
Chemother [Internet]. 2014 Jun;58(6):3085-90. 
[DOI:10.1128/AAC.02050-13] [PMID] [PMCID] 
40. Tzouvelekis LS, Markogiannakis A, Psichogiou M, 
Tassios PT, Daikos GL. Carbapenemases in Klebsiella 
pneumoniae and other Enterobacteriaceae: an evolving 
crisis of global dimensions. Clin Microbiol Rev 
[Internet]. 2012 Oct;25(4):682-707. 
[DOI:10.1128/CMR.05035-11] [PMID] [PMCID] 
41. Ma L, Wang J-T, Wu T-L, Siu LK, Chuang Y-C, Lin J-
C, et al. Emergence of OXA-48-Producing Klebsiella 
pneumoniae in Taiwan. PLoS One [Internet]. 
2015;10(9):e0139152. 
[DOI:10.1371/journal.pone.0139152] [PMID] [PMCID] 
42. Fursova NK, Astashkin EI, Knyazeva AI, Kartsev NN, 
Leonova ES, Ershova ON, et al. The spread of bla OXA-
48 and bla OXA-244 carbapenemase genes among 
Klebsiella pneumoniae, Proteus mirabilis and 
Enterobacter spp. isolated in Moscow, Russia. Ann Clin 
Microbiol Antimicrob [Internet]. 2015 Dec 2;14(1):46. 
[DOI:10.1186/s12941-015-0108-y] [PMID] [PMCID] 
43. Rimrang B, Chanawong A, Lulitanond A, Wilailuckana 
C, Charoensri N, Sribenjalux P, et al. Emergence of 
NDM-1- and IMP-14a-producing Enterobacteriaceae in 
Thailand. J Antimicrob Chemother [Internet]. 2012 Nov 
1;67(11):2626-30. [DOI:10.1093/jac/dks267] [PMID] 
44. Fazeli H, Norouzi-Barough M, Ahadi AM, Shokri D, 
Solgi H. Detection of New Delhi Metallo-Beta-
Lactamase-1 (NDM-1) in carbapenem- resistant 
Klebsiella pneumoniae isolated from a university 
hospital in Iran. Hippokratia [Internet]. 2015;19(3):205-
9. 
45. Solgi H, Giske CG, Badmasti F, Aghamohammad S, 
Havaei SA, Sabeti S, et al. Emergence of carbapenem 
resistant Escherichia coli isolates producing bla NDM 
and bla OXA-48 -like carried on IncA/C and IncL/M 
plasmids at two Iranian university hospitals. Infect Genet 
Evol [Internet]. 2017 Nov;55:318-23. 
[DOI:10.1016/j.meegid.2017.10.003] [PMID] 
46. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie 
Johnson J, Morgan DJ. Emergence of Klebsiella 
pneumoniae Carbapenemase-Producing Bacteria. South 
Med J [Internet]. 2011 Jan;104(1):40-5. 
[DOI:10.1097/SMJ.0b013e3181fd7d5a] [PMID] 
[PMCID] 
47. Nordmann P, Cuzon G, Naas T. The real threat of 
Klebsiella pneumoniae carbapenemase-producing 
bacteria. Lancet Infect Dis [Internet]. 2009 Apr;9(4):228-
36. [DOI:10.1016/S1473-3099(09)70054-4] 
48. Solgi H, Badmasti F, Aminzadeh Z, Giske CG, 
Pourahmad M, Vaziri F, et al. Molecular characterization 
of intestinal carriage of carbapenem-resistant 
Enterobacteriaceae among inpatients at two Iranian 
university hospitals: first report of co-production of bla 
NDM-7 and bla OXA-48. Eur J Clin Microbiol Infect Dis 
[Internet]. 2017 Nov 21;36(11):2127-35. 
[DOI:10.1007/s10096-017-3035-3] [PMID] 
49. Jamal WY, Albert MJ, Rotimi VO. High Prevalence of 
New Delhi Metallo-β-Lactamase-1 (NDM-1) Producers 
among Carbapenem-Resistant Enterobacteriaceae in 
Kosar Jalalvand et al. 95 
Vol.15 No.2 Spring 2020                                                                                    IRANIAN JOURNAL OF PATHOLOGY 
Kuwait. Galdiero M, editor. PLoS One [Internet]. 2016 
Mar 31;11(3):e0152638. 
[DOI:10.1371/journal.pone.0152638] [PMID] [PMCID] 
50. Dandachi I, Salem Sokhn E, Najem E, Azar E, Daoud Z. 
Carriage of beta-lactamase-producing 
Enterobacteriaceae among nursing home residents in 
north Lebanon. Int J Infect Dis [Internet]. 2016 
Apr;45:24-31. [DOI:10.1016/j.ijid.2016.02.007] [PMID] 
51. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. 
Mechanisms responsible for the emergence of 
carbapenem resistance in Pseudomonas aeruginosa. 
Hippokratia [Internet]. 2012 Oct;16(4):303-7. 
52. Messaoudi A, Haenni M, Mansour W, Saras E, Bel Haj 
Khalifa A, Chaouch C, et al. ST147 NDM-1-producing 
Klebsiella pneumoniae spread in two Tunisian hospitals. 
J Antimicrob Chemother [Internet]. 2017;72(1):315-6. 
[DOI:10.1093/jac/dkw401] [PMID] 
53. Seiffert SN, Marschall J, Perreten V, Carattoli A, Furrer 
H, Endimiani A. Emergence of Klebsiella pneumoniae 
co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, 
QnrA and ArmA in Switzerland. Int J Antimicrob Agents 








Jalalvand K. et al. Evaluation of Phenotypic and Genotypic Characteristics of Carbapenemases-producing 
Enterobacteriaceae and Its Prevalence in a Referral Hospital in Tehran City. Iranian Journal of Pathology, 2020; 
15(2): 
 
How to Cite This Article 
